Recombinant Helicobacter pylori neutrophil-activating protein fused with Maltose-binding protein (rMBP-NAP), a potential TLR2 ligand, was reported to possess immunomodulatory effects on in-situ tumor in our previous study. In present work, we attempt to elucidate the effect of rMBP-NAP at the local immune modulation in B16-F10-induced metastatic lung cancer. Our results demonstrated that growth of B16-F10 melanoma metastases in the lung was significantly arrested after rMBP-NAP treatment, along with marked reduction in metastatic lung nodules and significant increase in survival. The treatment induced both local and systemic immune responses, which associated with higher influx of CD4 + /CD8 + T cells and drove toward Th1-like and cytotoxic immune environment. Moreover, rMBP-NAP also showed significant anti-angiogenic activity by reducing vascularization in lung tumor sections.
Introduction
Metastatic lung cancer is one of the principal causes of death. It is a low immunogenic cancer, resistant to the surveillance of the immune system (Pinto et al. 2011; Igney and Krammer 2002) . Despite advances in treatment, the prognosis remains poor 5 years survival benefit.
Although, in the past 20 years, the Food and Drug Administration has approved the systemic administration of interferon (IFN)-α for patients in stage II or III with high risk of metastatic disease, the stimulating interest is still focus on development of new therapeutic strategies (de Melo et al. 2015) . The terminology of "cancer immunoediting" has been used to describe the process of shaping the immunogenicity of tumors, which relies upon the activation of the adaptive immune system to recognize and eliminate "transformed" cells (Prendergast 2008; Forte et al. 2012) . However, the tumor microenvironment is characterized by a process of chronic inflammation, which can facilitate either tumor establishment or progression (Colotta et al. 2009 ). Therefore, the activation of the immune system could represent a means to induce tumor regression (Igney and Krammer 2002; Prendergast 2008) .
Over a century ago, Dr. William Coley injected microorganisms that we now know include a number of Toll-like receptor (TLR) agonists into tumors and observed systemic antitumor responses (Mellman et al. 2011; Takeda et al.2003; Liew et al. 2005) . Following activation by ligands, TLRs can enhance the uptake of pathogens by phagocytic cells and also mediate leukocyte recruitment to pathologic focus through secreting multiple cytokines and chemokines (Mogensen 2009; Hajishengallis and Lambris 2011) . On the other hand, TLRs also express on adaptive immune cells and modulate the correlation between subsets of T cells and innate immune cells (Caron et al. 2005; Zhang et al. 2011 ). Based on the broad immune D r a f t activation effect, TLR agonists become attractive candidates for adjuvants of cancer immunotherapy.
Increasing evidence suggests that TLRs are important regulators of tumor biology, however,
little is known about their function in metastatic lung cancer. In order to understand the connection between TLRs and metastatic lung cancer progression, several TLR agonists are currently being tested as immunomodulator for anticancer therapies (Pinto et al. 2011; Forte et al. 2012) . The TLR2 ligand, Helicobacter pylori neutrophil-activating protein (Hp-NAP), has been shown to possess a potential role as biological response modifier. Hp-NAP is a key factor driving Th1 inflammation in H. pylori infection. Furthermore, recombinant Hp-NAP itself could serve as a potential drug candidate in immunotherapy of cancer (Codolo et al. 2012; Iankov et al. 2012; Ramachandran et al. 2013) . Our previous study demonstrated that the recombinant Hp-NAP fused with the maltose-binding protein of Escherichia coli (rMBP-NAP), possesses a significant immunomodulating effects on in-situ tumor, rather than direct killing of tumor cells (Wang et al. 2015) .
The present study is focused on the effect of rMBP-NAP that acts as an immunomodulator in the experimental mouse model of B16F10 melanoma lung metastasis. We show that rMBP-NAP can induce both local and systemic immune responses, which associated with 
Mice treatment
Mice were injected (i.v.) with 2×10 5 B16-F10 cells (day 1), and after 24 h rMBP-NAP (0.5, 2.5, or 5 mg/kg; 6 mice each group) was administered by the i.p. route for 7 times once every two days. Mice were administrated saline or cisplatinum (2 mg/kg; Sigma-Aldrich, Rome, Italy) as control group (n=6) and positive control group (n=6). Mice were euthanized 2 weeks after melanoma cells injection, the lungs were excised, and the pulmonary metastatic tumors were counted in a blind manner under a dissecting microscope.
For survival analysis, animals (n=5) were treated with 10 consecutive doses of the protein prior to tumor inoculation and were injected intravenously with 2×10 5 B16-F10 cells after rMBP-NAP treatment. We registered the day of death for each mouse and these data were used to Kaplan-Meier survival analysis.
Preparation of fusion protein rMBP-NAP

D r a f t
The involved experiment procedures were all based on our previous published works ( Kang et al. 2005) . Briefly, neutrophil-activating protein gene of H pylori (Hp-napA) was subcloned from the recombinant plasmid pNEB-napA (restored in our laboratory), digested with EcoR I
and Sal I (Takara, Japan) and inserted into the pMAL-c2x (New England Biolabs, Inc, USA)
vector which prepared with the same enzymes to make pMAL-c2x-napA. The sequence confirmed plasmids were transformed into the E.coli strain TB1 (Invitrogen). The transformed cells were grown in LB medium containing 50 µg/ml kanamycin in 100 ml batches at 37 ℃.
IPTG was added to the medium to a final concentration of 0.3 mM when the OD 600 of the culture reached 0.5. The expression of the fusion proteins was allowed for 3 h at 37 ℃. The cells were harvested and frozen at -20 ℃ overnight, sonicated in ice-water bath, centrifuged at 9000 rpm for 30 min at 4 ℃. Soluble rMBP-NAP in the supernatant was purified by amylose affinity chromatography. Endotoxin was removed with agarose bed columns containing immobilized polymyxin B (Thermo scientific, USA).
Polymerase chain reaction (PCR)
Total RNA was extracted with Trizol® (Invitrogen, USA) according to the manufacturer's instructions. Homogenize tissue samples in Trizol (1 ml per 50 mg of tissue) in appropriate homogenizer. Add 0.2 ml of chloroform per ml of Trizol used. Centrifuge the resulting mixture at 12,000 rpm for 15 minutes at 2-8 ℃. Transfer the aqueous phase to a fresh tube and add 0.5 ml of 2-propanol. Centrifuge and remove the supernatant, then wash the RNA pellet by adding a minimun of 1 ml of 75% ethanol and centrifuge at 12000 rpm for 5 minutes at 2-8 ℃. Briefly dry the RNA pellet by air-drying. Total RNA was dissolved in RNase-free water and prepared for qRT-PCR analysis.
D r a f t
Quantitative real time PCR was performed using the SYBR Premix Ex TaqTMⅡ(Takara, Japan). Data was acquired using a LightCycler 1.5 System (ligheCycler, German). Cycle threshold values were normalized to amplification of β-actin. Relative quantification of gene expression levels was calculated using the 2 −∆∆Ct methods. A list of the qRT-PCR primers used in the present study was given in suppl. Table S1 .
Isolation of splenocytes, lymphocytes and PBMC
Spleens from individual mice were removed and disrupted by scratching in a sterile manner, Cells suspended in PBS were centrifuged at 1000 rpm for 5 minutes and red blood cell osmotic lysis was carried out after incubation with 10 ml of QB LysingTM Solution Buffer (Quantobio, China). Centrifuging and removing the supernatant, the cell pellet was resuspended in 2 ml of RPMI-1640 medium and the viable splenocytes were counted by Trypan blue exclusion.
Lungs were removed, minced and incubated at 37℃ for 45 min in PBS containing 1 mg/ml collagenase D and 0.2 mg/ml DNase I (Sigma-Aldrich, USA). After enzyme treatment, lung tissue was gently passed through a cell strainer (70µm, BD falcon, USA) and then washed twice in PBS. Cells were resuspended in 35% Percoll (GE Healthcare, USA) in PBS, layered over 70% Percoll, and spun at 2,500 rpm for 20 min. Lymphocytes collected from the interface were used for subsequent flow cytometry analysis.
Peripheral blood was collected by orbital sinus bleeding in a tube containing citrate sodium buffer. Anti-coagulated blood was layered onto Histopaque-1083 (Sigma-Aldrich, USA) and peripheral blood mononuclear cells (PBMC) were purified by gradient centrifugation according to the manufacturer's recommendations.
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IFN-γ ELISPOT assay
IFN-γ-secreting splenocytes were enumerated using enzyme-linked immunospot (ELISPOT) (Lycke and Coico 1996) . Briefly, the splenocytes (1×10 7 cells/ml) obtained from rMBP-NAP and PBS administrated tumor-bearing mice, were added to Immunospot plates (Dakewe Biotech, China), which precoated with an anti-IFN-γ monoclonal antibody (mAb). Then, rMBP-NAP or PBS was added respectively. The positive control well was added PHA (Sigma-Aldrich, USA). The plates were incubated overnight at 37℃ under humidified air with 5% CO 2 . The wells were washed with deionized water and wash buffer and then incubated with biotin-conjugated anti-IFN-γ mAb at 37℃ for 1h. After washes, streptavidin-alkaline phosphatase was added and the plates were incubated for 1h at room temperature. The plates were again washed and added activator solution (Dakewe Biotech, China) to develop spots, then washed with distilled water to stop the reaction. Air dry completely at room temperature. Experiments were performed in triplicate. The number of spots in each well was counted using the BioReader 4000 Pro-X.
Cytotoxicity assay
The B16-F10 cells (0.5×10 4 ) in DMEM were used as target cells and incubated with PBMC, obtained from rMBP-NAP and PBS treated mice, for 4 h at 37 °C in a humidified atmosphere containing 5% CO 2 . The cytotoxicity was determined by LDH release assay using a commercially available kit (Promega, USA). 
Immunohistochemistry staining
Immunohistochemical studies were performed on 5-mm-thick sections prepared from formalin-fixed and paraffin-embedded tissue using standard staining protocols.
Deparaffinization and antigen retrieval were carried out as a standard procedure. Microvessel density (MVD) represented by CD34 staining was measured according to the methods (Weidner et al. 1991) . The resultant sections were first examined at low magnifications (4×) to identify the vascular-rich area in the tumor. Within this area, the CD34-positive microvessels were counted in a single high-power (20×) field. Any CD34 stained single or cluster of cells was considered a single countable microvessel.
Statistics
Results are expressed as means ± SEM. Changes observed in treated groups compared with controls were analyzed using GraphPad Prism 5.01 followed by unpaired two-tailed Student's t test, and/or two-way ANOVA where appropriate. The p values<0.05 was considered to be statistically significant.
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Results rMBP-NAP decreases lung metastatic tumor growth and prolongs survival of mice
The immunotherapeutic effect of the association of rMBP-NAP was evaluated in the metastatic B16F10 melanoma model. The challenge with viable B16F10 tumor cells occurred on day 1, C57Bl/6 mice were treated with seven intraperitoneal inoculations of rMBP-NAP at one day intervals after the tumor bearing. 24 hours after the last treatment, mice were killed for lung nodules quantification and/or immunological assays (Fig. 1A) .
Administration of rMBP-NAP promoted a marked reduction in the number of lung nodules in B16F10 injected mice (Fig. 1B) . Lung metastasis frequencies significantly were reduced by 43.9%, 71.9%, and 56.9% in rMBP-NAP treated mice at dosage of 0.5mg/kg, 2.5mg/kg, 5mg/kg, respectively, and the number of lung foci in cisplatinum-treated group was reduced to 41.6%, compared with that of PBS-treated mice (Fig. 1C) . According to the results above the dose of 2.5 mg/kg of rMBP-NAP was chosen in the following assays. The weight of lung tissues was markedly reduced in response to rMBP-NAP vs PBS control, while no significant change in body weight ( Fig. 1D and 1E ). For survival analysis, mice inoculated with rMBP-NAP showed a prolonged survival in comparison to animals treated with PBS (Fig.1F ).
This observation indicates that rMBP-NAP treatment reduces development of metastatic nodules in the lungs. The results showed when an effector/target ratio (E/T ratio) of 10:1 was used, the cytotoxic efficacy of PBMC cells and splenic lymphocytes from rMBP-NAP treated mice were remarkably augmented compared with control mice (Fig. 2C ).
rMBP-NAP can exhibit the immune regulatory effect in the tumor microenvironment
It is becoming clear that tumors can actively subvert the immune system through a variety of immune suppressive mechanisms within the tumor microenvironment. To verify the cytokine profiles induced by rMBP-NAP in the tumor microenvironment, we performed a quantification of cytokines in mice lung homogenates. To this end, lung tissues from rMBP-NAP treated or untreated mice were excised. As shown in Fig.3A and 3B, the expression of Th1-like cytokine profiles such as IFN-γ and IL27 were significantly increased.
In other hand, the mRNA expression of proinflammatory cytokines (IL-6, TGF-β) and chemokines (CCL2、CCL20) were remarkably decreased (shown in Fig. 3C ). To verify the role of T lymphocytes in the protective antitumor effect induced by rMBP-NAP, we examined the types of infiltrating cells within the lung tissue and found that CD3 + CD8 + T cells were D r a f t significantly augmented after treatment (Fig.3D ). In addition, the adhesion molecules ICAM-1, and VCAM-1 which is important regulator to the recruitment of effector T lymphocyes, were significantly enhenced compared with control (Fig.3E ). These data indicated that rMBP-NAP has potential activity to regulate the tumor immunosuppressive microenvironment and enhance the adaptive cell immunity.
rMBP-NAP decreases VEGF levels in the lungs of tumor-bearing mice
To explore the involvement of suppression of angiogenesis in the antitumor activity induced by rMBP-NAP, we evaluated the inhibitory effect of rMBP-NAP on tumor-induced neovascularization by immunohistochemical staining of lung tissue section with anti-CD34
antibody. As shown in Fig. 4A , the microvessel which stained by anti-CD34 is much less in rMBP-NAP treated mice compared with control. Furthermore, qRT-PCR analysis also showed the production of antiangiogenic cytokines, VEGF-A and VEGF-D, were decreased in the tumor sections with rMBP-NAP treatment ( Fig. 4B and 4C ).
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Discussion
Immunotherapy is emerging as a powerful and active tumor-specific approach against cancer via triggering the immune system. TLR agonists used as single agents can effectively eradicate tumors due to their potent stimulation of innate and adaptive immunity.
TLRs are fundamental elements of the immune system, which facilitate our understanding of the innate and adaptive immune pathways. TLR signaling could lead to tumor cell death, 
